These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 34271161)

  • 1. Representativeness of the VICTORIA Trial Population in Clinical Practice: Analysis of the PINNACLE Registry.
    Butler J; Djatche LM; Lautsch D; Yang L; Patel MJ; Mentz RJ
    J Card Fail; 2021 Dec; 27(12):1374-1381. PubMed ID: 34271161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medication Trajectory and Treatment Patterns in Medicare Patients With Heart Failure and Reduced Ejection Fraction.
    Mentz RJ; Lautsch D; Pulungan Z; Kim S; Hilkert R; Teigland C; Yang M; Djatche L
    J Card Fail; 2022 Aug; 28(8):1349-1354. PubMed ID: 34930657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Machine Learning Algorithms for Predicting Hospital Readmissions and Worsening Heart Failure Events in Patients With Heart Failure With Reduced Ejection Fraction: Modeling Study.
    Ru B; Tan X; Liu Y; Kannapur K; Ramanan D; Kessler G; Lautsch D; Fonarow G
    JMIR Form Res; 2023 Apr; 7():e41775. PubMed ID: 37067873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-centered Outcomes in HFrEF Following a Worsening Heart Failure Event: A Survey Analysis.
    Dunbar SB; Tan X; Lautsch D; Yang M; Ricker B; Maculaitis MC; Nagle T; Clark LT; Hilkert R; Brady JE; Spertus JA
    J Card Fail; 2021 Aug; 27(8):877-887. PubMed ID: 34364664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial.
    Pieske B; Patel MJ; Westerhout CM; Anstrom KJ; Butler J; Ezekowitz J; Hernandez AF; Koglin J; Lam CSP; Ponikowski P; Roessig L; Voors AA; O'Connor CM; Armstrong PW;
    Eur J Heart Fail; 2019 Dec; 21(12):1596-1604. PubMed ID: 31820546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology of Worsening Heart Failure in a Population-based Cohort from Alberta, Canada: Evaluating Eligibility for Treatment With Vericiguat.
    Sepehrvand N; Islam S; Dover DC; Kaul P; McAlister FA; Armstrong PW; Ezekowitz JA
    J Card Fail; 2022 Aug; 28(8):1298-1308. PubMed ID: 35589087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial.
    Armstrong PW; Roessig L; Patel MJ; Anstrom KJ; Butler J; Voors AA; Lam CSP; Ponikowski P; Temple T; Pieske B; Ezekowitz J; Hernandez AF; Koglin J; O'Connor CM
    JACC Heart Fail; 2018 Feb; 6(2):96-104. PubMed ID: 29032136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial.
    Lam CSP; Giczewska A; Sliwa K; Edelmann F; Refsgaard J; Bocchi E; Ezekowitz JA; Hernandez AF; O'Connor CM; Roessig L; Patel MJ; Pieske B; Anstrom KJ; Armstrong PW;
    JAMA Cardiol; 2021 Jun; 6(6):706-712. PubMed ID: 33185650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applicability of Vericiguat to Patients Hospitalized for Heart Failure in the United States.
    Khan MS; Xu H; Fonarow GC; Lautsch D; Hilkert R; Allen LA; DeVore AD; Alhanti B; Yancy CW; Albert NM; Butler J; Greene SJ
    JACC Heart Fail; 2023 Feb; 11(2):211-223. PubMed ID: 36754528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Budget Impact Analysis of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Event.
    Alsumali A; Lautsch D; Liu R; Patel D; Nanji S; Djatche LM
    Adv Ther; 2021 May; 38(5):2631-2643. PubMed ID: 33860924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction: The VICTORIA echocardiographic substudy.
    Pieske B; Pieske-Kraigher E; Lam CSP; Melenovský V; Sliwa K; Lopatin Y; Arango JL; Bahit MC; O'Connor CM; Patel MJ; Roessig L; Morris DA; Kropf M; Westerhout CM; Zheng Y; Armstrong PW;
    Eur J Heart Fail; 2023 Jul; 25(7):1012-1021. PubMed ID: 36994634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug Treatment of Heart Failure with Reduced Ejection Fraction: Defining the Role of Vericiguat.
    Coats AJS; Tolppanen H
    Drugs; 2021 Sep; 81(14):1599-1604. PubMed ID: 34478114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Classification of Heart Failure Events by Severity: Insights From the VICTORIA Trial.
    Felker GM; North R; Mulder H; Jones WS; Anstrom KJ; Patel MJ; Butler J; Ezekowitz JA; Lam CSP; O'Connor CM; Roessig L; Hernandez AF; Armstrong PW;
    J Card Fail; 2023 Aug; 29(8):1113-1120. PubMed ID: 37331690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction.
    Butler J; Yang M; Manzi MA; Hess GP; Patel MJ; Rhodes T; Givertz MM
    J Am Coll Cardiol; 2019 Mar; 73(8):935-944. PubMed ID: 30819362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vericiguat for the treatment of heart failure with reduced ejection fraction.
    Siddiqi AK; Greene SJ; Fudim M; Mentz RJ; Butler J; Khan MS
    Expert Rev Cardiovasc Ther; 2023 Apr; 21(4):245-257. PubMed ID: 36881733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective.
    Alsumali A; Djatche LM; Briggs A; Liu R; Diakite I; Patel D; Wang Y; Lautsch D
    Pharmacoeconomics; 2021 Nov; 39(11):1343-1354. PubMed ID: 34623625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Outcome Predictions for the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial: VICTORIA Outcomes Model.
    Mentz RJ; Mulder H; Mosterd A; Sweitzer NK; Senni M; Butler J; Ezekowitz JA; Lam CSP; Pieske B; Ponikowski P; Voors AA; Anstrom KJ; Armstrong PW; O'Connor CM;
    J Card Fail; 2021 May; ():. PubMed ID: 34216757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial.
    Voors AA; Mulder H; Reyes E; Cowie MR; Lassus J; Hernandez AF; Ezekowitz JA; Butler J; O'Connor CM; Koglin J; Lam CSP; Pieske B; Roessig L; Ponikowski P; Anstrom KJ; Armstrong PW;
    Eur J Heart Fail; 2021 Aug; 23(8):1313-1321. PubMed ID: 33999486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world eligibility for vericiguat in decompensated heart failure with reduced ejection fraction.
    Oh J; Lee CJ; Park JJ; Lee SE; Kim MS; Cho HJ; Choi JO; Lee HY; Hwang KK; Kim KH; Yoo BS; Choi DJ; Baek SH; Jeon ES; Kim JJ; Cho MC; Chae SC; Oh BH; Kang SM
    ESC Heart Fail; 2022 Apr; 9(2):1492-1495. PubMed ID: 35142095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Outcome Predictions for the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial.
    Mentz RJ; Mulder H; Mosterd A; Sweitzer NK; Senni M; Butler J; Ezekowitz JA; Lam CSP; Pieske B; Ponikowski P; Voors AA; Anstrom KJ; Armstrong PW; O'connor CM; Hernandez AF;
    J Card Fail; 2021 Jun; ():. PubMed ID: 34217593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.